Antiviral and immunological benefits in HIV patients receiving intranasal peptide T (DAPTA)

@article{Polianova2003AntiviralAI,
  title={Antiviral and immunological benefits in HIV patients receiving intranasal peptide T (DAPTA)},
  author={M. Polianova and F. Ruscetti and C. Pert and R. Tractenberg and G. Leoung and S. Strang and M. Ruff},
  journal={Peptides},
  year={2003},
  volume={24},
  pages={1093-1098}
}
D-Ala-Peptide T-amide (DAPTA), the first viral entry inhibitor, blocks chemokine (CCR5) receptors, not CD4. Early investigators could not "replicate" DAPTAs potent in vitro antiviral effect using the lab-adapted, X4, peptide T-insensitive strain, IIIB, delaying clinical virological studies. We now report that DAPTA, administered to eleven long-term infected (mean=17 years) patients with stable persistent plasma "virus" for up to 32 weeks did not change this level. Infectious virus could not be… Expand
Chemokine receptor-5 (CCR5) is a receptor for the HIV entry inhibitor peptide T (DAPTA).
TLDR
The capability of DAPTA to potently block gp120-CD4 binding to the major co-receptor CCR5 explains its molecular and therapeutic mechanism of action as a selective antiviral entry inhibitor for R5 tropic HIV-1 isolates. Expand
The transport of anti-HIV drugs across blood–CNS interfaces: Summary of current knowledge and recommendations for further research
TLDR
Current knowledge on the transport of anti-HIV drugs across the blood–brain barrier and the choroid plexus is summarised, as well as recommendations for future research are provided. Expand
Investigational drugs in HIV: Pros and cons of entry and fusion inhibitors (Review).
TLDR
This study reviewed articles, clinical trials, and conference communications about all the drugs under investigation belonging to the class of entry and fusion inhibitors that are at least in phase I clinical trials. Expand
HIV, Antiretroviral Therapies, and the Brain
TLDR
Recent studies demonstrate that CART regimens with higher central nervous system (CNS) penetration effectiveness ranks may improve neurocognitive functioning, and earlier treatment initiation may be considered to protect the CNS. Expand
Polycyclic peptide and glycopeptide antibiotics and their derivatives as inhibitors of HIV entry
TLDR
Antiviral activity and other biological properties of two groups of polycyclic peptides are discussed and can be envisaged as potential lead compounds for application as microbicides against sexual HIV transmission. Expand
Neuropathic pain inhibitor, RAP-103, is a potent inhibitor of microglial CCL1/CCR8
TLDR
It is reported here that RAP‐103 exhibits stronger antagonism for CCR8 compared to CCR5 in chemotaxis using primary cultured mouse microglia, suggesting that C CR8, among other chemokine receptors such as CCR2/CCR5, could be the most potent target for R AP‐103. Expand
Strategies for Intranasal Delivery of Therapeutics for the Prevention and Treatment of NeuroAIDS
TLDR
Using this intranasal method in animal models, researchers have successfully reduced stroke damage, reversed Alzheimer’s neurodegeneration, reduced anxiety, improved memory, stimulated cerebral neurogenesis, and treated brain tumors. Expand
Adjunctive therapies for AIDS dementia complex.
TLDR
This review confirms the absence of evidence that any of the adjunctive therapies improves cognitive performance or quality of life, or both for patients with ADC, though they were well tolerated and safe. Expand
Effects of peptides, with emphasis on feeding, pain, and behavior A 5-year (1999-2003) review of publications in Peptides.
TLDR
By presenting in condensed form the effects of peptides which are essential for systems biology, it is hoped that this summary of existing knowledge will encourage additional novel research to be presented in Peptides. Expand
Effects of peptides, with emphasis on feeding, pain, and behavior A 5-year (1999–2003) review of publications in Peptides
TLDR
By presenting in condensed form the effects of peptides which are essential for systems biology, it is hoped that this summary of existing knowledge will encourage additional novel research to be presented in Peptides. Expand
...
1
2
...

References

SHOWING 1-10 OF 19 REFERENCES
Peptide T inhibits HIV-1 infection mediated by the chemokine receptor-5 (CCR5).
TLDR
Results show that peptide T selectively inhibits HIV replication using chemokine receptor CCR5 compared to CXC4, explaining past inconsistencies of in vitro antiviral effects. Expand
Update on D-ala-peptide T-amide (DAPTA): a viral entry inhibitor that blocks CCR5 chemokine receptors.
TLDR
Clinical data showing peptide T's immunomodulation of plasma cytokine levels and increases in the percentage of IFNgamma secreting CD8+ T cells in patients with HIV disease are presented and suggests additional therapeutic mechanisms via regulation of specific immunity. Expand
Monocytes harbour replication-competent, non-latent HIV-1 in patients on highly active antiretroviral therapy
TLDR
Recovery of replication-competent virus from some HAART patients indicates that monocytes can also harbour HIV-1, and detection of circular, viral DNA and spliced RNA in these cells suggests that their infection is recent and transcriptionally active rather than latent. Expand
Detection of infectious HIV in circulating monocytes from patients on prolonged highly active antiretroviral therapy.
TLDR
The existence of a reservoir of resting CD4+ T cells harboring latent replication-competent HIV has been demonstrated in patients on prolonged highly active antiretroviral therapy (HAART) and may constitute a second HIV reservoir. Expand
Human immunodeficiency virus type 1 protease inhibitors.
TLDR
Four protease inhibitors, saquinavir mesylate, ritonavir, nelfinavir, and indinavir sulfate, have been approved by the Food and Drug Administration and other agents are undergoing active investigation. Expand
Impact of antiretroviral therapy and changes in virus load on human immunodeficiency virus (HIV)-specific T cell responses in primary HIV infection.
TLDR
Whether HAART was initiated before or after seroconversion had little effect on HIV-specific CD4(+) and CD8(+) T cell responses. Expand
Stability in controlling viral replication identifies long-term nonprogressors as a distinct subgroup among human immunodeficiency virus type 1-infected persons
TLDR
The idea that LTNPs may be a pathophysiologically distinct subgroup among persons infected with HIV-1 is supported, as the predictive value of HIV- 1 mRNA expression in PBMCs at postseroconversion was found to be limited but significantly increased during the first year of infection. Expand
In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors
TLDR
Five resistant variants isolated from patients undergoing therapy with the protease inhibitor MK-639 exhibited cross-resistance to all members of a panel of six structurally diverse protease inhibitors, suggesting that com-bination therapy with multiple protease inhibition may not prevent loss of antiviral activity resulting from resistance selection. Expand
CD4+ T cell kinetics and activation in human immunodeficiency virus-infected patients who remain viremic despite long-term treatment with protease inhibitor-based therapy.
TLDR
T cell dynamics were studied in human immunodeficiency virus-infected patients who continued using antiretroviral therapy despite detectable plasma viremia, indicating that partial virus suppression reduces CD4(+) cell turnover and activation, thereby resulting in sustained CD4 (+) cell gains, and that measurements of T cell dynamics may provide an in vivo marker of viral virulence. Expand
Evolution of Phenotypic Drug Susceptibility and Viral Replication Capacity during Long-Term Virologic Failure of Protease Inhibitor Therapy in Human Immunodeficiency Virus-Infected Adults
TLDR
It is concluded that HIV may be constrained in its ability to become both highly resistant and highly fit and that this may contribute to the continued partial suppression of plasma HIV RNA levels that is observed in some patients with drug-resistant viremia. Expand
...
1
2
...